Literature DB >> 28370686

Pregnancy and maternal chronic hepatitis B infection-Evidence of reproductive advantage?

Terence T Lao1, Daljit S Sahota1.   

Abstract

PROBLEM: As multiparas have high prevalence of chronic hepatitis B virus (HBV) infection, we examined here the relationship between the number of pregnancies with HBV infection. METHOD OF STUDY: Retrospective cohort study examining the prevalence of HBV infection by actual gravidity and parity in 104 242 gravidae managed during 1997-2013.
RESULTS: Infection rate increased from 8.5% to 10.6% for G1 to G≥6 and from 8.8% to 10.0% for P0 to P≥3 (P<.001). When stratified by parity, correlation with gravidity was maintained in the nulliparous gravidae. For the same gravidity, increasing parity was associated with higher rate of HBV infection for G2 and G3. Multiparas had higher HBV infection prevalence (all >10%) than nulliparas (<10%) for G2 to G≥4.
CONCLUSION: Prior pregnancies, especially successful ones, are associated with increased HBV infection in an endemic population, which could have enhanced reproduction and in the process facilitated its transmission to the following generations.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  abortion; fertility; gravidity; hepatitis B surface antigen; parity

Mesh:

Year:  2017        PMID: 28370686     DOI: 10.1111/aji.12667

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  2 in total

1.  Regional differences and temporal trend analysis of Hepatitis B in Brazil.

Authors:  Giuliano Grandi; Luis Fernandez Lopez; Marcelo Nascimento Burattini
Journal:  BMC Public Health       Date:  2022-10-17       Impact factor: 4.135

2.  Chronic maternal hepatitis B virus infection and pregnancy outcome- a single center study in Kunming, China.

Authors:  Qian Sun; Terence T Lao; Mingyu Du; Min Xie; Yonghu Sun; Bing Bai; Junnan Ma; Tianying Zhu; Shengnan Yu; Runmei Ma
Journal:  BMC Infect Dis       Date:  2021-03-10       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.